Find uplifting stories about heroes, innovations, and solutions
150 results for "kras inhibitors"
After decades of slow progress, breakthrough drugs targeting a genetic mutation found in 90% of pancreatic cancers are nearing FDA approval in 2026. The KRAS inhibitors now in late-stage trials could transform treatment for one of medicine's deadliest diseases.
A breakthrough drug called daraxonrasib is giving hope to pancreatic cancer patients after scientists spent nearly 50 years trying to target the KRAS mutation. Patients like 36-year-old Leanna Stokes are living far longer than expected thanks to this medical breakthrough.
A breakthrough drug from Revolution Medicines is giving real hope to pancreatic cancer patients for the first time in decades. The pill, called daraxonrasib, successfully targeted KRAS, a protein scientists once thought was impossible to drug.
A breakthrough drug targeting previously "undruggable" KRAS mutations has approximately doubled survival time for metastatic pancreatic cancer patients compared to chemotherapy. The development marks a historic shift for a disease that affects over 90% of pancreatic cancer cases. --- ##
A new combination therapy for aggressive prostate cancer just got FDA approval, along with two tests that help doctors match the right patients to this targeted treatment. This breakthrough could help up to 30% of men with advanced prostate cancer find a treatment plan designed specifically for their genes.
A breakthrough drug called daraxonrasib targets the "undruggable" mutation behind 90% of pancreatic cancers, nearly doubling survival time in a major clinical trial. Patients lived 13.2 months compared to 6.7 months with standard chemotherapy.
University of Pennsylvania researchers eliminated precancerous pancreatic cells in mice before they became tumors, nearly doubling survival time. It's the first proof that medical intervention can stop pancreatic cancer at its earliest stage.
Mount Sinai researchers discovered that severe anemia in cancer patients taking PARP inhibitors often stems from a treatable folate deficiency, not unavoidable side effects. A simple folic acid supplement could help thousands stay on life-saving treatment.
More than a million breast cancer patients have benefited from CDK inhibitors, and researchers at Roswell Park are now working to extend these life-saving benefits to other cancer types. New drug combinations and precision medicine approaches could help more patients live longer with fewer side effects.
A new triple therapy treatment completely eliminated pancreatic tumors in mice, offering hope for one of the deadliest cancers. The breakthrough could transform treatment for the 67,000 Americans diagnosed each year.
A new pill targeting the KRAS mutation doubles survival time in pancreatic cancer patients, marking the biggest treatment breakthrough ever for one of the world's deadliest cancers. After 25 years of research and $17 million in funding, scientists are finally seeing progress on multiple fronts at once.
Researchers in Spain have found a triple-drug combination that eliminates pancreatic tumors in mice without them returning. The breakthrough could eventually transform treatment for one of cancer's deadliest forms.
Scientists have finally cracked a genetic mutation once thought impossible to treat, potentially transforming outcomes for 90% of pancreatic cancer patients. A new drug targeting KRAS mutations has doubled survival time compared to traditional chemotherapy.
A breakthrough medication targeting a previously "undruggable" genetic mutation could transform treatment for one of the deadliest cancers. Patients in late-stage trials lived nearly twice as long when taking the new drug alongside chemotherapy.
Northwestern University researchers developed a breakthrough therapy that grabs "undruggable" cancer proteins and drags them to the cell's trash system for destruction. The approach worked against MYC and KRAS, two proteins that drive many aggressive cancers and resist most treatments.
The FDA just approved Beqalzi, the first BCL2 inhibitor for patients with relapsed mantle cell lymphoma who've tried other treatments. Over half the patients in trials responded to the new therapy, offering fresh hope for those with limited options.
Scientists at Florida A&M University discovered an experimental compound that makes deadly pancreatic cancer cells essentially kill themselves. The treatment blocked over 90% of cancer cell movement, offering new hope for one of the most lethal cancers.
A new pill called daraxonrasib has doubled survival time for advanced pancreatic cancer patients in a groundbreaking 500-person trial. Oncologists are calling it a grand slam after four decades of failed attempts to crack the disease.
British researchers discovered why identical cancer treatments work brilliantly for some patients but fail others. The breakthrough could help doctors personalize therapies and save thousands of lives.
Researchers discovered a way to make treatment-resistant cancer cells vulnerable again by breaking down their DNA repair machinery. The breakthrough could help millions of patients whose cancers stopped responding to existing therapies.
Showing 20 of 150